- Full Description
- OACP IE LTD is an ISO 13485-certified and CE-IVDR compliant medical diagnostics company transforming cancer molecular pathology. Standard In Situ Hybridization (FISH) diagnostics require 2–3 days—a bottleneck causing delayed therapies, 126,000 preventable deaths annually, and substantial healthcare costs.
OACP solves this crisis through a proprietary, two-engine platform requiring zero workflow disruption or capital equipment changes:
Accelerated Chemistry: Patented catalysts compress hybridization from 18 hours to 40 minutes, achieving 2-hour total test time (>98% concordance) while cutting lab operating costs by up to 50%.
Digital Pathology AI (AICP): An expert co-pilot trained on 30,000+ cases delivering automated, audit-ready quality control in <30 seconds to eliminate pre-analytical failures and standardize scoring. Fully de-risked with granted global patents (EU, USA, China, India) and >$1M in commercial traction, OACP collaborates with industry leaders and the University of Michigan Rogel Cancer Center. OACP is scaling globally from Ireland, Italy, and Saudi Arabia to make same-day precision oncology standard care
- Areas of focus
- Molecular Diagnostics / Oncology Diagnostics, Molecular Pathology, ISH/FISH, IVD, Digital Pathology, Clinical AI
- Problem Statement
- Cancer diagnostics faces a critical bottleneck: genetic In Situ Hybridization (FISH) is the gold standard for targeted therapy selection, yet standard workflows require 2 to 3 working days due to slow overnight hybridization (12–18 hours).
This diagnostic lag triggers a devastating clinical crisis. Each month of treatment delay increases cancer mortality risk by 10%, causing an estimated 126,000 preventable deaths globally each year and burdening healthcare systems with $20 billion in avoidable costs from late-stage interventions.
Compounding this time barrier is a severe global talent gap.
With only 12.5 pathologists per million people, under-resourced laboratories struggle with complex protocols, inconsistent staining, and pre-analytical sample preparation failures.
Without rapid turnaround and standardized quality control, oncologists cannot deliver timely precision therapies, turning curable diagnoses into late-stage tragedies.